Last reviewed · How we verify
ALN-PCSSC
At a glance
| Generic name | ALN-PCSSC |
|---|---|
| Also known as | PCSK9 synthesis inhibitor, Inclisiran |
| Sponsor | The Medicines Company |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Inclisiran Versus Placebo for the Prevention of Major Adverse Cardiovascular and Limb Events in Patients Undergoing Percutaneous Coronary Intervention or Peripheral Endovascular Intervention (PHASE4)
- Real World Adherence of PCSK9 Targeted Therapy
- A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients. (PHASE3)
- Lp(a) Lowering Study of Pelacarsen (TQJ230) With Background Inclisiran in Participants With Elevated Lp(a) and Established ASCVD (PHASE3)
- The Belgian REAL (BE.REAL) Registry
- Coronary Computed Tomography Study to Assess the Effect of Inclisiran in Addition to Maximally Tolerated Statin Therapy on Atherosclerotic Plaque Progression in Participants With a Diagnosis of Non-obstructive Coronary Artery Disease Without Previous Cardiovascular Events (PHASE3)
- Evaluation of Efficacy and Safety of Early in Hospital Initiation of Inclisiran Treatment in Patients With Acute Coronary Syndromes (PHASE3)
- Study to Evaluate Safety, Tolerability and Efficacy of Inclisiran in Children With Homozygous Familial Hypercholesterolemia (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ALN-PCSSC CI brief — competitive landscape report
- ALN-PCSSC updates RSS · CI watch RSS
- The Medicines Company portfolio CI